Provided by Tiger Fintech (Singapore) Pte. Ltd.

IGC Pharma

0.3482
+0.00080.23%
Post-market: 0.34830.0001+0.03%19:51 EDT
Volume:887.34K
Turnover:317.89K
Market Cap:29.21M
PE:-3.74
High:0.3600
Open:0.3464
Low:0.3380
Close:0.3474
Loading ...

IGC Pharma Announces Promising Preclinical Results for Alzheimer’s Drug Candidate IGC-M3 Targeting Multiple Disease Pathways

Reuters
·
Yesterday

IGC Pharma Inc. Announces Date for Annual Stockholders' Meeting

Reuters
·
04 Aug

IGC Pharma Inc. Announces New AI-Enhanced Clinical Trial for Alzheimer's Drug Discovery at AAIC 2025

Reuters
·
23 Jul

IGC Pharma iles to sell 4.74M shares of common stock for holders

TIPRANKS
·
19 Jul

IGC Pharma Unveils MINT-AD: Innovative AI Platform to Predict Alzheimer's Risk and Enhance Early Detection

Reuters
·
11 Jul

IGC Pharma Reports Transformative Year in Alzheimer’s Innovation

TIPRANKS
·
01 Jul

IGC Pharma Inc. Reports Fiscal 2025 Revenue Dip to $1.2M, Net Loss Improves to $7.1M, EPS at $0.09

Reuters
·
30 Jun

Options Volatility and Implied Earnings Moves This Week, June 30 – July 02, 2025

TIPRANKS
·
30 Jun

IGC Pharma Q4 EPS $(0.01) Beats $(0.02) Estimate, Sales $330.000K Beat $305.000K Estimate

Benzinga
·
28 Jun

IGC Pharma Inc. to Release Fiscal Year 2025 Financial Results

Reuters
·
27 Jun

IGC Pharma Expands Alzheimer's Dementia Agitation Treatment Trial to Yukon

MT Newswires Live
·
23 Jun

IGC Pharma Highlights Alzheimer’s Research Progress

TIPRANKS
·
17 Jun

IGC Pharma Inc. Launches New CALMA Phase 2 Clinical Trial Site in Puerto Rico to Address High Alzheimer's Prevalence

Reuters
·
22 May

IGC Pharma announces strategic investment from advisors

TIPRANKS
·
24 Apr

IGC Pharma Welcomes Strategic Investment from Advisors

ACCESS Newswire
·
24 Apr

IGC Pharma Expands Phase 2 Alzheimer's Trial Site

MT Newswires Live
·
08 Apr

IGC Pharma expands CALMA trial with addition of Butler Hospital Program

TIPRANKS
·
08 Apr

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

ACCESS Newswire
·
08 Apr

IGC Pharma Adds Canadian Site to Phase 2 Trial of Investigational Alzheimer's Dementia Therapy

MT Newswires Live
·
20 Mar

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

ACCESS Newswire
·
20 Mar